EP3853346A1 - Use of chloroplasts for oxygen production in cell cultures - Google Patents
Use of chloroplasts for oxygen production in cell culturesInfo
- Publication number
- EP3853346A1 EP3853346A1 EP19861733.4A EP19861733A EP3853346A1 EP 3853346 A1 EP3853346 A1 EP 3853346A1 EP 19861733 A EP19861733 A EP 19861733A EP 3853346 A1 EP3853346 A1 EP 3853346A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chloroplasts
- media
- oxygen
- million
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003763 chloroplast Anatomy 0.000 title claims abstract description 197
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 78
- 239000001301 oxygen Substances 0.000 title claims abstract description 78
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 238000004113 cell culture Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 60
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 30
- 239000001963 growth medium Substances 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 19
- 230000035899 viability Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 17
- 230000008569 process Effects 0.000 description 15
- 241000219315 Spinacia Species 0.000 description 11
- 235000009337 Spinacia oleracea Nutrition 0.000 description 11
- 239000002609 medium Substances 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000029553 photosynthesis Effects 0.000 description 5
- 238000010672 photosynthesis Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 241001185310 Symbiotes <prokaryote> Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000014306 paracrine signaling Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000013406 biomanufacturing process Methods 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006545 glycolytic metabolism Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
Definitions
- the disclosure relates generally to producing large quantities of oxygen for cell cultures and providing human cells with the ability to photosynthesize.
- the present disclosure provides methods for increasing oxygen concentration of a cellular media or cells.
- the present disclosure provides a method for increasing oxygen concentration in a culture media, the method comprising culturing chloroplasts in a culture media including one or more mammalian cells, wherein the chloroplasts remain external to the mammalian cells in the culture media; and exposing the chloroplasts to light to cause oxygen production by the chloroplasts to enrich the culture media with oxygen to promote the growth or differentiation of the mammalian cells.
- the present disclosure provides a method for increasing oxygen concentration, the method comprising coculturing chloroplasts with one or more mammalian cells in a media, wherein the mammalian cells under conditions that cause the one or more mammalian cells to take up the chloroplasts from the media; and increasing oxygen production in the mammalian cells by exposing the chloroplasts to light.
- the methods can further comprise isolating chloroplasts from a source material.
- the mammalian cells are human stem cells.
- the chloroplasts are provided in a concentration of about 8 million chloroplasts per ml of media and about 12 million chloroplasts per milliliter of the culture media.
- the chloroplasts are provided in a concentration of about 9 million chloroplasts per ml of media and about 11 million chloroplasts per milliliter of the culture media.
- the chloroplasts produce between about 70 and 90% oxygen in the culture media.
- the chloroplasts produce between about 80 and 90% oxygen in the culture media.
- the method may further comprise maintaining viability of chloroplasts for at least about 72 hours.
- the methods may further comprise maintaining viability of chloroplasts for between about 72 hours to about 120 hours.
- the methods may further comprise isolating chloroplasts from a source material.
- the present disclosure provides a culture medium comprising chloroplasts in a concentration of about 8 million chloroplasts per ml of media and about 12 million chloroplasts per milliliter of the culture media.
- the chloroplasts are provided in a concentration of about 9 million chloroplasts per ml of media and about 11 million chloroplasts per milliliter of the culture media.
- the chloroplasts produce between about 70 and 90% oxygen in the culture media.
- the chloroplasts produce between about 80 and 90% oxygen in the culture media.
- viability of chloroplasts is maintained for at least about 72 hours. In some embodiments, viability of chloroplasts is maintained for between about 72 hours to about 120 hours.
- the culture medium further comprises mammalian cells, wherein increasing oxygen production in the mammalian cells by exposing the chloroplasts to light.
- Figures 1A and 1B depict an example process for producing oxygen for cell cultures, in accordance with the present disclosure
- Figures 2A and 2B depict images of isolated chloroplasts plated in wells, in accordance with the present disclosure
- Figure 3 depicts a graph showing increased oxygen concentrations in media including chloroplasts, in accordance with the present disclosure
- Figure 4A depicts an image of chloroplast cocultures after the addition of chloroplasts to the culture, in accordance with the present disclosure.
- FIGs 4C and 4B depict images of chloroplast cocultures during the culture period, in accordance with the present disclosure.
- the present disclosure discusses methods and systems for increasing oxygen concentration of cells cultures and cells using isolated chloroplasts.
- the method involves extracellularly increasing oxygen concentration of human cell media by culturing isolated chloroplasts with the human cell media.
- the method involves intracellularly increasing oxygen concentration of human cells via coculture of isolated chloroplasts with human cells, facilitating chloroplast uptake and sequestration within cells.
- the chloroplasts can remain viable for over 48 hours or, in some embodiments, over 72 hours in culture and still produce significant amounts of oxygen for use by the human cells.
- the methods and systems of the present disclosure can be utilized to create temporary chloroplast-human cell symbionts that can conduct photosynthesis via coculture of isolated chloroplasts with human Mesenchymal Stem Cells (hMSCs).
- hMSCs human Mesenchymal Stem Cells
- such symbionts can uptake isolated chloroplasts and conduct photosynthesis in vitro and/or in vivo.
- the symbiotic chloroplast and human cells can be applied to different applications, such as for example, insertion into red blood cells for supporting mammalian cell growth or organism oxygenation.
- chloroplast when inserted into red blood cells, chloroplast can produce and carry oxygen in addition to oxygen normally contained in the red blood cells (oxygen supplement).
- oxygen supplement oxygen
- chloroplasts can function to produce glucose, amino acids and fatty acids.
- chloroplasts can be delivered by injection into human skin epithelial cells in vivo, providing nutrients for temporary nutritional supplementation.
- a method for extracellularly increasing oxygen concentration of a cellular media includes sterilely isolating chloroplasts from a source material, culturing the chloroplasts in at least one well plate with a media, wherein the chloroplasts remain separate from other cells in the media, and incubating and exposing the cultured chloroplasts to light in the at least one well plate to increase oxygen concentration.
- the source material can be spinach leaves or other plant material.
- a method for intracellularly increasing oxygen concentration of human cells media includes sterilely isolating chloroplasts from a source material, coculturing the chloroplasts in at least one well plate with human cell in a media, wherein the chloroplasts are taken up the human cells in the media, and incubating and exposing the cultured chloroplasts to light in the at least one well plate to increase oxygen concentration.
- the source material can be spinach leaves or another plant material.
- the human cells can be Mesenchymal Stem Cells (hMSCs) or dermal fibroblasts (hDF).
- Figures 1A and 1B depict example processes 100, 110 for implementing the methods of the present disclosure.
- Figure 1A depicts a process 100 for isolating and culturing chloroplasts in well plates with media to extracellularly increase oxygen concentration of human cells media, as shown in FIGS. 2A and 2B.
- chloroplasts are sterilely isolated from source materials.
- the chloroplasts are plated in wells with a media.
- the cultures including chloroplasts
- the results of process 100 is an increased dissolved oxygen concentration for the cells in the media.
- the resulting media can then be used for various medical implementations.
- the chloroplasts alone can be used to oxygenate media.
- FIG. 1B depicts a process 110 for isolating and coculturing chloroplasts with human cells to intracellularly increase oxygen concentration of human cells media.
- human cells can be Mesenchymal Stem Cells (hMSCs), human dermal fibroblasts (hDF), etc. In some embodiments, this can facilitate chloroplast uptake and sequestration within cells to increase oxygen concentration of human cells media.
- chloroplasts are sterilely isolated from source martials and are aliquoted into well plates containing a medium.
- the cells can be induced to take up chloroplasts in such a manner that the chloroplasts maintain its functions within a mammalian cell cytoplasm.
- the chloroplasts are co-cultured with cells (e.g., human cells) and are sequestered for a predetermined culture period well plates.
- the result of process 110 is the production of chloroplast-human symbionts for increased oxygen production.
- certain therapies require an oxygen source along with paracrine signaling from hMSCs, through creation of these symbiotes we should be able to achieve this in an acute non-toxic manner.
- this process could be applied to biotechnological production where oxygen levels are highly regulated.
- chloroplasts can be co-cultured with mammalian cells, but not taken up by the mammalian cells.
- the present methods can utilize different source materials for isolating chloroplast.
- the chloroplast may be isolated from any combination of plants and algal.
- the chloroplasts are isolated from spinach leaves.
- the isolated chloroplasts can be obtained from the plants or algal using any combination of methods.
- the chloroplast can be isolated from the source material by deveining and finely chopping the source material with a fine blade (e.g., step 102 of process 100).
- the chopped source material can be placed into a mortar along with a grinding solution and ground with a pestle until a paste-like consistency.
- the source material can be placed in 15 mL of grinding solution (0.33 M Sorbitol, 10 mM Sodium Pyrophosphate, 4 mM Magnesium Chloride, 2 mM Ascorbic Acid, pH was adjusted to 6.5). Thereafter, the paste can be filtered.
- the paste can be filtered through two layers of sterile cheesecloth and then spun down in a centrifuge at 300g for 1 minute at 4°C. Additionally, supernatant resulting from this process can be collected for further processing. For example, the supernatant can be collected and subsequently re-spun down in a centrifuge at lOOOg for 7 minutes at 4°C. The supernatant after the second centrifuge cycle can be removed and a pellet containing the chloroplasts can resuspended in a suspension solution. In some embodiments, a pellet having chloroplasts can be created by centrifuging the solution with the chloroplasts.
- the pellet containing the chloroplasts can be, for example, suspended in 5 mL of suspension solution (0.33 M Sorbitol, 2 mM Ethylenediaminetetraacetic acid, 1 mM Magnesium Chloride, 50 mM HEPES, with the pH adjusted to 7.6). After processing, the isolated chloroplasts can be counted using a hemocytometer before being used in subsequent steps.
- sterile chloroplasts can be isolated from spinach leaves and are plated in a well, with a media therein, for a predetermined period of time for culturing (e.g., step 104 of process 100).
- spinach cells can be plated in a well with a Mesenchymal Stem Cell Growth Medium (MSCGM) for three days, as discussed with respect to Figure 1A.
- MSCGM Mesenchymal Stem Cell Growth Medium
- Any cell culture medium can be used.
- the medium may be buffered with HEPES, but not sodium bicarbonate, and will not include penicillin- streptomycin.
- Gentamycin but can be used as an antibiotic and Amphotericin B can be used as an anti-fungal.
- normal mammalian cell culture medium including serums such as Fetal Bovine Serum can be used for these processes.
- the chloroplasts can be cultured in MSCGM alone or with additional chloroplasts. Thereafter, the chloroplasts can be incubated and exposed to light (e.g., step 106 of process 100).
- the chloroplasts can be used to prepare a culture medium.
- the present disclosure provides a culture medium comprising chloroplasts in a concentration of about 8 million chloroplasts per ml of media and about 12 million chloroplasts per milliliter of the culture media.
- Figure 2A depicts an image 200 taken at 20X enhancement showing freshly isolated chloroplasts 202, from a spinach leaf, plated in wells of a medium 204 at a concentration of 10 million chloroplasts 202 per mL of MSCGM medium 204.
- Figure 2B depicts an image 200 taken at 20X enhancement showing freshly isolated chloroplasts 202, from a spinach leaf, plated in wells of a medium 204 at a concentration of 1 million chloroplasts 202 per mL of MSCGM medium 204.
- the isolated chloroplasts 202 remained vibrant green and photosynthetically viable after isolation. In some embodiments, the chloroplasts remain viable for at least 72 hours.
- the chloroplasts remain viable between 48 hours and 120 hours. In some embodiments, the chloroplasts can remain viable for between about 72 hours to about 120 hours. In some embodiments, the isolated chloroplasts 202 can be cultured in the plated well of medium 204 for a predetermined period of time to produce oxygen.
- Figure 3 depicts a chart 300 showing how chloroplasts isolated from spinach leaf are able to increase oxygen concentration in media.
- Mesenchymal stem cell media or DMEM with FBS can be used.
- Figure 3 depicts a bar graph showing a first bar shows the percentage of oxygen produced with media 204 alone (about 18%) and the second bar shows the percent of oxygen produced with the isolated chloroplast 202 (about 10 million chloroplasts) in the media 204 (about 82%). The 82% oxygen level can be produced from isolated chloroplast within two days after isolation.
- the media may be supplemented between about 6 million chloroplasts per ml of media and about 12 million chloroplasts per ml of media. In some embodiments, the media may be supplemented between about 8 million chloroplasts per ml of media and about 12 million chloroplasts per ml of media. In some embodiments, the media may be supplemented between about 9 million chloroplasts per ml of media and about 11 million chloroplasts per ml of media. In some embodiments, the chloroplasts can produce between about 70 and 90% oxygen. In some embodiments, the chloroplasts can produce between about 75% and 85% oxygen. In some embodiments, the chloroplasts can produce between about 80% and 90% oxygen.
- the chart in Figure 3 shows that the presence of chloroplasts in culture media leads to strongly significant increases in media dissolved oxygen levels over the isolated chloroplasts cultured alone in human cell media. This increase in oxygen increases the possible applications for the media, as discussed in greater detail herein.
- spinach leaves can be utilized to create temporary chloroplast- human cell symbionts 206 that can conduct photosynthesis via coculture of isolated chloroplasts 202 with human Mesenchymal Stem Cells (hMSCs) 208, or any cell type that actively digests small particles so that the cells can uptake isolated chloroplasts 202, which can then conduct photosynthesis in vitro.
- hMSCs human Mesenchymal Stem Cells
- chloroplast-human symbionts 206 a solution containing sterilely isolated chloroplasts 202 can be aliquoted into well plates containing hMSCs. There are no specific steps or processes used for plating the chloroplasts in the wells, the hMSCs 208 and hDFs will inherently uptake the chloroplasts 202 when cocultured together. For example, within 30 minutes to 24 hours from the addition of chloroplasts to hMSC culture wells, chloroplasts will appear to be“naturally” and endosymbiotically incorporated into the cytoplasms of the hMSCs, remaining intracellularly sequestered until at least day 8 of the culture period.
- chloroplasts and cells can be 4-7 chloroplasts per cell.
- the symbiotes can be exposed to light through modification of the incubators where light strips (e.g., light emitting diodes (LEDs)) were attached to the rack directly above the cultures and were turned on for 12-hour periods of time. Chloroplast-human cell symbiotes survive up to a week after cocultures begin.
- LEDs light emitting diodes
- Figures 4A-4C depict images 400, 410, 420 demonstrating that viable, photosynthetically-functional chloroplasts 202 are incorporated and sequestered within hMSCs (in some capacity) using the process 110 discussed with respect to Figure 1B.
- Figure 4A depicts an image 400, taken at 20X enhancement, of chloroplast-hMSC cocultures 206 24 hours after the addition of chloroplasts 202 to the culture 204.
- chloroplasts 202 appear to be incorporated by hMSCs and residing within their cytoplasms.
- Figure 4B depicts an image 410, taken at 20X enhancement, of chloroplast-hMSC cocultures 206 on day 4 of the culture period.
- chloroplasts 202 have remained sequestered within hMSCs remain bright green and viable. Some hMSCs have morphologies resembling those of hMSC-derived chondrocytes.
- Figure 4C depicts an image 420, taken at 20X enhancement, of chloroplast-hMSC cocultures 206 on day 8 of the culture period. As shown in Figure 4C, hMSCs still appear to have sequestered chloroplasts 202 within their cytoplasms, and hMSCs continue to adopt a spherical morphology characteristic of chondrocytes. Thus, chloroplasts are able to be incorporated by hMSCs in vitro and remain sequestered and photosynthetically functional for at least 8 days after their uptake.
- Chloroplasts also are non-toxic to mammalian cells and thusly could be incorporated into biomanufacturing of pharmaceuticals where oxygen level regulations are necessary to provide for positive manufacturing of the drug products. Additionally, the lack of money, time, and training with which oxygen concentration can be increased and photosynthesis can be induced using the chloroplast protocols discussed herein.
- chloroplast-human cell symbionts and isolated chloroplasts in culture.
- isolated chloroplasts could be used to enhance cell cultures with oxygen production, to grow full organs or tissues in vitro, to vascularize and regenerate ischemic tissues, to quicken wound healing, to enhance human performance and physical ability, to produce oxygen in hypoxic environments (e.g. polluted environments or outer space), and to grow clean meat in vitro for consumption.
- Chloroplast-human cell symbionts and the process of endosymbiotic chloroplast uptake could be used to facilitate the destruction of cancerous tumours, to deliver biomolecules (e.g.
- the chloroplasts can be used for internal or external wound healing.
- the chloroplasts may be delivered as part of a cream, ointment, or lotion that can be applied to an external wound.
- a wound dressing impregnated with chloroplasts is provided.
- the chloroplasts may be delivered to an internal wound using, for example, a biocompatible polymer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734314P | 2018-09-21 | 2018-09-21 | |
| PCT/US2019/052231 WO2020061500A1 (en) | 2018-09-21 | 2019-09-20 | Use of chloroplasts for oxygen production in cell cultures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3853346A1 true EP3853346A1 (en) | 2021-07-28 |
| EP3853346A4 EP3853346A4 (en) | 2022-06-01 |
Family
ID=69888943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19861733.4A Withdrawn EP3853346A4 (en) | 2018-09-21 | 2019-09-20 | USE OF CHLOROPLASTS FOR OXYGEN PRODUCTION IN CELL CULTURES |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3853346A4 (en) |
| CA (1) | CA3110233A1 (en) |
| WO (1) | WO2020061500A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585530B (en) * | 2023-05-05 | 2024-02-02 | 暨南大学 | An efficient oxygen-producing chloroplast composite hydrogel and its preparation method and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2389958A1 (en) * | 2010-03-22 | 2011-11-30 | Technische Universität Klinikum Rechts der Isar | Use of photosynthetic scaffolds in tissue engineering |
| WO2016037010A1 (en) * | 2014-09-03 | 2016-03-10 | Symbiox, Inc. | Photosynthetic cellular substances and methods of use thereof |
| JP6744665B2 (en) * | 2015-06-25 | 2020-08-19 | 学校法人東京女子医科大学 | Method for culturing animal cell composition, method for producing animal cell composition using the same, and animal cell composition |
-
2019
- 2019-09-20 WO PCT/US2019/052231 patent/WO2020061500A1/en not_active Ceased
- 2019-09-20 CA CA3110233A patent/CA3110233A1/en active Pending
- 2019-09-20 EP EP19861733.4A patent/EP3853346A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3110233A1 (en) | 2020-03-26 |
| WO2020061500A1 (en) | 2020-03-26 |
| EP3853346A4 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bédard et al. | Innovative human three-dimensional tissue-engineered models as an alternative to animal testing | |
| Papadopoulos et al. | Clinical applications of adipose-derived stem cell (ADSC) exosomes in tissue regeneration | |
| Takahashi et al. | Harvest of quality-controlled bovine myogenic cells and biomimetic bovine muscle tissue engineering for sustainable meat production | |
| Bhat et al. | Prospectus of cultured meat—advancing meat alternatives | |
| Olmedo-Moreno et al. | Heterogeneity of in vitro expanded mesenchymal stromal cells and strategies to improve their therapeutic actions | |
| CN112190592B (en) | Application of miRNA in preparation of osteoarthritis prevention and treatment drugs, miRNA high-expression exosome and application | |
| US20100035327A1 (en) | Use of rice-derived products in a universal cell culture medium | |
| Dinescu et al. | Sericin enhances the bioperformance of collagen-based matrices preseeded with human-adipose derived stem cells (hADSCs) | |
| Paaske Utheim et al. | Culture of oral mucosal epithelial cells for the purpose of treating limbal stem cell deficiency | |
| AU2019273006B2 (en) | System for cell culture in a bioreactor | |
| Galuzzi et al. | Human engineered cartilage and decellularized matrix as an alternative to animal osteoarthritis model | |
| CN116694474A (en) | New exosome preparation method for skin care product and application thereof | |
| CN109112101A (en) | A kind of fibroblast culture medium and its application | |
| Grabowska et al. | Adipose tissue-derived stromal cells in matrigel impact the regeneration of severely damaged skeletal muscles | |
| Blando et al. | Can a scaffold enriched with mesenchymal stem cells be a good treatment for spinal cord injury? | |
| CN114703126A (en) | Muscle stem cell separation and extraction, novel hydrolysate culture system and application thereof | |
| Wei et al. | Hydrogels to support transplantation of human embryonic stem cell-derived retinal pigment epithelial cells | |
| CN111534477B (en) | Method for culturing primary epithelial stem cell balls of lung tissue of mouse | |
| EP3853346A1 (en) | Use of chloroplasts for oxygen production in cell cultures | |
| Huang et al. | Culture conditions for human induced pluripotent stem cell-derived Schwann cells: a two-centre study | |
| CN105754943A (en) | Culture method of naked mole rat hippocampal neurons | |
| CN118956641A (en) | A fermented Lactobacillus mucilaginosus TG017 postbiotic for regulating intestinal cell development and its application | |
| Huynh et al. | Fiber and electrical field alignment increases BDNF expression in SH-SY5Y cells following electrical stimulation | |
| KR102142254B1 (en) | Method for improving separation efficiency of urine stem cells using 3,4'-dihydroxyflavones and promoting hematopoietic stem cell differentiation efficiency of urine stem cell-derived pluripotent stem cells | |
| CN104877954A (en) | Stem cell niche as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210302 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220503 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0775 20100101ALI20220427BHEP Ipc: C12N 5/0797 20100101ALI20220427BHEP Ipc: C12N 5/0789 20100101ALI20220427BHEP Ipc: C12N 5/07 20100101AFI20220427BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20221201 |